ADMA Biologics, Inc. (ADMA): Operating Cash Flow
$50.40M
Year ended 2025-12-31
$136.72M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.40M | -57.5% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $118.67M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $8.80M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$59.51M | n/m | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | -$112.37M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$102.00M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$76.19M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$62.68M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$37.27M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | -$18.27M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$15.42M | n/m | 2017-02-24, From 2015-01-01 |
| 2014-12-31 | -$14.70M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$10.89M | n/m | 2015-03-09, From 2013-01-01 |
| 2012-12-31 | -$6.90M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$1.43M | n/a | 2013-03-06, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $50.40M | -57.5% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$12.45M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$10.71M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $200.87M | +62.7% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$47.63M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $117.42M | -33.1% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $347.37M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$45.99M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $51.91M | -10.8% |
Compare ADMA, TARS, IMCR, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗